On September 7, 2022 Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, reported that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022 (Press release, Xenetic Biosciences, SEP 7, 2022, https://ir.xeneticbio.com/news/detail/126/xenetic-biosciences-inc-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference [SID1234619132]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Xenetic Biosciences, Inc., Wednesday, September 7, 2022, Press release picture
In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.

A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 12 at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company’s website (www.xeneticbio.com). The webcast replay will be archived for 90 days following the event.

On September 7, 2022 Seagen Inc. (Nasdaq:SGEN) reported that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022 at 12:55 p.m. Eastern Time (Press release, Seagen, SEP 7, 2022, View Source [SID1234619131]). The presentation will be webcast live and available for replay from the investor section of Seagen’s website at investor.seagen.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 7, 2022 Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, reported that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022 (Press release, Outlook Therapeutics, SEP 7, 2022, View Source [SID1234619130]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 12 at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.

On September 7, 2022 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, reported that HOOKIPA’s management team will participate in the following upcoming investor conferences (Press release, Hookipa Pharma, SEP 7, 2022, View Source [SID1234619128]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley Global Healthcare Conference, September 12-14, New York
Fireside Chat: September 13, 12:55pm ET
H.C. Wainwright Global Investment Conference, September 12-14, New York
The Morgan Stanley Fireside Chat webcast will be available within the Investors & Media section of HOOKIPA’s website at View Source Archived replays will be accessible for 30 days following each event.

On September 7, 2022 GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Harout Semerjian, Chief Executive Officer, will present in-person at the H.C. Wainwright 24th Annual Global Investment Conference in New York, NY on Wednesday, September 14, 2022 at 3:00 p.m. ET (Press release, GlycoMimetics, SEP 7, 2022, View Source [SID1234619127]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

An archived recording of the presentation will be available for 90 days on the GlycoMimetics website at View Source